Skip to main content
Top
Published in: Clinical and Translational Oncology 6/2016

01-06-2016 | Research Article

Prognostic value of tropomyosin-related kinases A, B, and C in gastric cancer

Authors: A. Kamiya, M. Inokuchi, S. Otsuki, H. Sugita, K. Kato, H. Uetake, K. Sugihara, Y. Takagi, K. Kojima

Published in: Clinical and Translational Oncology | Issue 6/2016

Login to get access

Abstract

Purpose

Tropomyosin-related kinase (Trk) receptors play critical roles in tumor development and are considered attractive targets for cancer therapy. We investigated correlations of the expression of TrkA, TrkB, and TrkC with clinicopathological features and outcomes in gastric cancer.

Methods

Tumor samples were obtained from 221 patients with gastric cancer who underwent gastrectomy between 2003 and 2007. The expression of TrkA, TrkB, and TrkC was analyzed using immunohistochemical staining. The relationship of their expression to clinicopathological factors and outcomes was assessed.

Results

High expression of TrkA, TrkB, or TrkC was significantly associated with histopathology (p = 0.022, p < 0.001, and p < 0.001). High expression of TrkA was significantly correlated with variables related to tumor progression, including lymph node metastasis (p = 0.024) and distant metastasis or recurrence (p < 0.001). Distant metastasis or recurrence was found in a significantly higher proportion of patients with high expression of TrkC than in those with low expression (p = 0.036). High expression of TrkA was significantly associated with poorer relapse-free survival (RFS) in univariate analysis (p = 0.001). High expression of TrkA or TrkC was significantly associated with poorer disease-specific survival (DSS) in univariate analysis (p < 0.001 and p = 0.008). In multivariate analysis, TrkA was an independent predictor of RFS [hazard ratio (HR), 2.294; 95 % confidence interval (CI), 1.309–4.032; p = 0.004] and DSS (HR, 2.146; 95 % CI, 1.195–3.861; p = 0.011). Expression of TrkB was not associated with RFS or DSS in univariate analysis.

Conclusions

Our results demonstrated that TrkA expression was associated with tumor progression and poor survival, and was an independent predictor of poor outcomes in gastric cancer patients.
Literature
1.
go back to reference Matsuda A, Matsuda T. Time trends in stomach cancer mortality (1950–2008) in Japan, the USA and Europe based on the WHO mortality database. Jpn J Clin Oncol. 2011;41(7):932–3.CrossRefPubMed Matsuda A, Matsuda T. Time trends in stomach cancer mortality (1950–2008) in Japan, the USA and Europe based on the WHO mortality database. Jpn J Clin Oncol. 2011;41(7):932–3.CrossRefPubMed
2.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, Fr Int Agency Res Cancer. 2013. http://globocan.iarc.fr. Accessed 23 Jan 2015. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, Fr Int Agency Res Cancer. 2013. http://​globocan.​iarc.​fr. Accessed 23 Jan 2015.
3.
go back to reference Maehara Y, Oshiro T, Endo K, Baba H, Oda S, Ichiyoshi Y, et al. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery. 1996;119:397–402.CrossRefPubMed Maehara Y, Oshiro T, Endo K, Baba H, Oda S, Ichiyoshi Y, et al. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery. 1996;119:397–402.CrossRefPubMed
4.
go back to reference Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;13:215–21.CrossRef Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;13:215–21.CrossRef
5.
go back to reference Hirono Y, Tsugawa K, Fushida S, Ninomiya I, Yonemura Y, Miyazaki I, et al. Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology. 1995;52:182–8.CrossRefPubMed Hirono Y, Tsugawa K, Fushida S, Ninomiya I, Yonemura Y, Miyazaki I, et al. Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology. 1995;52:182–8.CrossRefPubMed
6.
go back to reference García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 2003;10:234–41.CrossRefPubMed García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 2003;10:234–41.CrossRefPubMed
7.
go back to reference Hirashima Y, Yamada Y, Matsubara J, Takahari D, Okita N, Takashima A, et al. Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci. 2009;100:310–5.CrossRefPubMed Hirashima Y, Yamada Y, Matsubara J, Takahari D, Okita N, Takashima A, et al. Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci. 2009;100:310–5.CrossRefPubMed
8.
go back to reference Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, et al. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer. 2015. doi:10.1007/s1012001505188. Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, et al. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer. 2015. doi:10.​1007/​s1012001505188.
9.
go back to reference Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy vs. chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;13:687–97.CrossRef Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy vs. chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;13:687–97.CrossRef
10.
go back to reference Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol. 2014;15:1224–35.CrossRefPubMed Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol. 2014;15:1224–35.CrossRefPubMed
11.
go back to reference Hondermarck H. Neurotrophins and their receptors in breast cancer. Cytokine Growth Factor Rev. 2012;23(6):357–65.CrossRefPubMed Hondermarck H. Neurotrophins and their receptors in breast cancer. Cytokine Growth Factor Rev. 2012;23(6):357–65.CrossRefPubMed
12.
go back to reference Dang C, Zhang Y, Ma Q, Shimahara Y. Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J Gastroenterol Hepatol. 2006;21(5):850–8.CrossRefPubMed Dang C, Zhang Y, Ma Q, Shimahara Y. Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J Gastroenterol Hepatol. 2006;21(5):850–8.CrossRefPubMed
13.
go back to reference Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, et al. Expression levels of the nerve growth factor receptors TrkA and p75 in effusion and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res. 2001;7(11):3457–64.PubMed Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, et al. Expression levels of the nerve growth factor receptors TrkA and p75 in effusion and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res. 2001;7(11):3457–64.PubMed
14.
go back to reference Sasahira T, Ueda N, Yamamoto K, Bhawal UK, Kurihara M, Kirita T, et al. Trks are novel oncogenes involved in the induction of neovascularization, tumor progression, and nodal metastasis in oral squamous cell carcinoma. Clin Exp Metastasis. 2013;30(2):165–76.CrossRefPubMed Sasahira T, Ueda N, Yamamoto K, Bhawal UK, Kurihara M, Kirita T, et al. Trks are novel oncogenes involved in the induction of neovascularization, tumor progression, and nodal metastasis in oral squamous cell carcinoma. Clin Exp Metastasis. 2013;30(2):165–76.CrossRefPubMed
15.
go back to reference Sasahira T, Ueda N, Kurihara M, Matsushima S, Ohmori H, Fujii K, et al. Tropomyosin receptor kinases B and C are tumor progressive and metastatic marker in colorectal carcinoma. Hum Pathol. 2013;44(6):1098–106.CrossRefPubMed Sasahira T, Ueda N, Kurihara M, Matsushima S, Ohmori H, Fujii K, et al. Tropomyosin receptor kinases B and C are tumor progressive and metastatic marker in colorectal carcinoma. Hum Pathol. 2013;44(6):1098–106.CrossRefPubMed
16.
go back to reference Zhang Y, Fujiwara Y, Doki Y, Takiguchi S, Yasuda T, Miyata H, et al. Overexpression of tyrosine kinase B protein as a predictor for distant metastases and prognosis in gastric carcinoma. Oncology. 2008;75(1–2):17–26.CrossRefPubMed Zhang Y, Fujiwara Y, Doki Y, Takiguchi S, Yasuda T, Miyata H, et al. Overexpression of tyrosine kinase B protein as a predictor for distant metastases and prognosis in gastric carcinoma. Oncology. 2008;75(1–2):17–26.CrossRefPubMed
17.
go back to reference Tanaka K, Shimura T, Kitajima T, Kondo S, Ide S, Okugawa Y, et al. Tropomyosin-related receptor kinase B at the invasive front and tumour cell dedifferentiation in gastric cancer. Br J Cancer. 2014;110(12):2923–34.CrossRefPubMedPubMedCentral Tanaka K, Shimura T, Kitajima T, Kondo S, Ide S, Okugawa Y, et al. Tropomyosin-related receptor kinase B at the invasive front and tumour cell dedifferentiation in gastric cancer. Br J Cancer. 2014;110(12):2923–34.CrossRefPubMedPubMedCentral
18.
go back to reference Okugawa Y, Tanaka K, Inoue Y, Kawamura M, Kawamoto A, Hiro J, et al. Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer. Br J Cancer. 2013;108(1):121–30.CrossRefPubMedPubMedCentral Okugawa Y, Tanaka K, Inoue Y, Kawamura M, Kawamoto A, Hiro J, et al. Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer. Br J Cancer. 2013;108(1):121–30.CrossRefPubMedPubMedCentral
19.
go back to reference Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene. 2009;7(18):1960–70.CrossRef Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene. 2009;7(18):1960–70.CrossRef
20.
go back to reference Fujikawa H, Tanaka K, Toiyama Y, Saigusa S, Inoue Y, Uchida K, et al. High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells. J Gastroenterol. 2012;47:775–84.CrossRefPubMed Fujikawa H, Tanaka K, Toiyama Y, Saigusa S, Inoue Y, Uchida K, et al. High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells. J Gastroenterol. 2012;47:775–84.CrossRefPubMed
21.
go back to reference Skaper SD. The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol. 2012;846:1–12.CrossRefPubMed Skaper SD. The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol. 2012;846:1–12.CrossRefPubMed
22.
go back to reference Schecterson LC, Bothwell M. Neurotrophin receptors: old friends with new partners. Dev Neurobiol. 2010;70:332–8.PubMed Schecterson LC, Bothwell M. Neurotrophin receptors: old friends with new partners. Dev Neurobiol. 2010;70:332–8.PubMed
24.
go back to reference Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001;169(2):107–14.CrossRefPubMed Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001;169(2):107–14.CrossRefPubMed
25.
go back to reference Thiele CJ, Li Z, McKee AE. On Trk–the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res. 2009;15(19):5962–7.CrossRefPubMedPubMedCentral Thiele CJ, Li Z, McKee AE. On Trk–the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res. 2009;15(19):5962–7.CrossRefPubMedPubMedCentral
26.
go back to reference Jin W, Yun C, Kim HS, Kim SJ. TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling. Cancer Res. 2007;67:9869–77.CrossRefPubMed Jin W, Yun C, Kim HS, Kim SJ. TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling. Cancer Res. 2007;67:9869–77.CrossRefPubMed
27.
go back to reference Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23:2078–93.CrossRefPubMed Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23:2078–93.CrossRefPubMed
28.
go back to reference Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ, et al. Transforming growth factor β induces apotosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res. 2008;68:3152–60.CrossRefPubMed Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ, et al. Transforming growth factor β induces apotosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res. 2008;68:3152–60.CrossRefPubMed
29.
go back to reference Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011;68(4):1057–65.CrossRefPubMedPubMedCentral Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011;68(4):1057–65.CrossRefPubMedPubMedCentral
30.
go back to reference Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, et al. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther. 2007;6(9):1360–7.CrossRefPubMedPubMedCentral Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, et al. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther. 2007;6(9):1360–7.CrossRefPubMedPubMedCentral
Metadata
Title
Prognostic value of tropomyosin-related kinases A, B, and C in gastric cancer
Authors
A. Kamiya
M. Inokuchi
S. Otsuki
H. Sugita
K. Kato
H. Uetake
K. Sugihara
Y. Takagi
K. Kojima
Publication date
01-06-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1407-7

Other articles of this Issue 6/2016

Clinical and Translational Oncology 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine